Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
45.04
+6.17 (15.87%)
At close: Nov 6, 2026, 4:00 PM EST
45.28
+0.24 (0.53%)
After-hours: Nov 6, 2026, 7:30 PM EST

Edgewise Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
52.8140.0231.8723.4517.6311.03
Research & Development
165.37151.39126.9790.9154.0332.19
Operating Expenses
218.18191.41158.83114.3671.6643.22
Operating Income
-218.18-191.41-158.83-114.36-71.66-43.22
Interest & Investment Income
31.9823.6125.0214.194.020.4
Pretax Income
1,165-167.8-133.81-100.16-67.64-42.81
Net Income
1,010-167.8-133.81-100.16-67.64-42.81
Net Income to Common
1,010-167.8-133.81-100.16-67.64-42.81
Net Income Growth
------
Shares Outstanding (Basic)
10710392645438
Shares Outstanding (Diluted)
11610392645438
Shares Change
16.12%11.38%45.02%18.90%42.82%4977.96%
EPS (Basic)
9.40-1.63-1.45-1.57-1.26-1.14
EPS (Diluted)
8.68-1.63-1.45-1.57-1.26-1.14
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-202.28-144.07-110.34-97.69-58.18-34.18
Free Cash Flow Per Share
-1.74-1.40-1.19-1.53-1.09-0.91
EBITDA
-216.05-189.32-156.76-112.81-71.29-42.94
D&A For EBITDA
2.132.082.071.550.370.27
EBIT
-218.18-191.41-158.83-114.36-71.66-43.22
SEC Filings: 10-K · 10-Q